Market Cap
US$185.5m
Last Updated
2020/05/31 06:17 UTC
Data Sources
Company Financials +
Executive Summary
OncoCyte Corporation engages in the development and commercialization of non-invasive blood-based diagnostic tests for the early detection of cancer.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Adequate balance sheet and slightly overvalued.
Similar Companies
Share Price & News
How has OncoCyte's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OCX's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-0.7%
OCX
0.5%
US Biotechs
3.0%
US Market
1 Year Return
-29.8%
OCX
27.3%
US Biotechs
9.9%
US Market
Return vs Industry: OCX underperformed the US Biotechs industry which returned 27.3% over the past year.
Return vs Market: OCX underperformed the US Market which returned 9.9% over the past year.
Shareholder returns
| OCX | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.7% | 0.5% | 3.0% |
| 30 Day | 9.1% | 9.2% | 8.2% |
| 90 Day | 22.1% | 12.8% | 0.4% |
| 1 Year | -29.8%-29.8% | 28.6%27.3% | 12.4%9.9% |
| 3 Year | -51.2%-51.2% | 34.7%30.2% | 31.0%22.3% |
| 5 Year | n/a | -1.9%-7.8% | 58.1%40.3% |
Price Volatility Vs. Market
How volatile is OncoCyte's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
The CEO, President & Director of OncoCyte Corporation (NYSEMKT:OCX), Ronald Andrews, Just Bought 40% More Shares2 months ago | Simply Wall St
What Kind Of Shareholder Appears On The OncoCyte Corporation's (NYSEMKT:OCX) Shareholder Register?4 months ago | Simply Wall St
Did OncoCyte Corporation (NYSEMKT:OCX) Insiders Buy Up More Shares?Valuation
Is OncoCyte undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OCX ($2.76) is trading below our estimate of fair value ($13.41)
Significantly Below Fair Value: OCX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OCX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: OCX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OCX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OCX is overvalued based on its PB Ratio (4.7x) compared to the US Biotechs industry average (3.7x).
Next Steps
Future Growth
How is OncoCyte forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
59.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OCX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OCX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OCX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OCX's revenue (61.8% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: OCX's revenue (61.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OCX is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has OncoCyte performed over the past 5 years?
-22.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OCX is currently unprofitable.
Growing Profit Margin: OCX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OCX is unprofitable, and losses have increased over the past 5 years at a rate of -22.5% per year.
Accelerating Growth: Unable to compare OCX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: OCX has a negative Return on Equity (-71.79%), as it is currently unprofitable.
Next Steps
Financial Health
How is OncoCyte's financial position?
Financial Position Analysis
Short Term Liabilities: OCX's short term assets ($18.1M) exceed its short term liabilities ($6.9M).
Long Term Liabilities: OCX's short term assets ($18.1M) exceed its long term liabilities ($16.0M).
Debt to Equity History and Analysis
Debt Level: OCX's debt to equity ratio (8.4%) is considered satisfactory.
Reducing Debt: OCX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OCX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OCX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 33.7% each year
Next Steps
Dividend
What is OncoCyte's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OCX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OCX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OCX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OCX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OCX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.0yrs
Average management tenure
CEO
Ronnie, Ron Andrews (59yo)
0.83
Tenure
US$2,102,212
Compensation
Mr. Ronald A. Andrews, Jr., also known as Ronnie or Ron, has been Chief Executive Officer and President of OncoCyte Corporation since July 1, 2019 and is its Director since April 2018. Mr. Andrews has been ...
CEO Compensation Analysis
Compensation vs Market: Ronnie, Ron's total compensation ($USD2.10M) is above average for companies of similar size in the US market ($USD1.38M).
Compensation vs Earnings: Ronnie, Ron's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 0.83yr | US$2.10m | 0.093% $173.1k | |
| Chief Financial Officer | 2.42yrs | US$1.16m | 0.040% $73.4k | |
| Chief Scientific Officer | 1.17yrs | US$1.22m | 0.0013% $2.4k | |
| no data | US$1.63m | 0.0052% $9.7k | ||
| COO & Secretary | 1.75yrs | no data | no data | |
| Senior VP & Chief Accounting Officer | 0.75yr | no data | 0.015% $27.6k | |
| Senior Vice President of Commercial Marketing & Market Access | 0.33yr | no data | no data | |
| Chief Medical Officer | 0.17yr | no data | no data | |
| Scientific Advisor | 4.58yrs | US$328.84k | no data |
1.0yrs
Average Tenure
65yo
Average Age
Experienced Management: OCX's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 0.83yr | US$2.10m | 0.093% $173.1k | |
| Independent Director | 4.83yrs | US$130.34k | 0.15% $282.8k | |
| Director | 10.58yrs | US$105.34k | 0.41% $755.9k | |
| Independent Chairman of the Board | 2yrs | US$155.10k | 0.078% $144.8k | |
| Independent Director | 0.83yr | US$90.34k | no data | |
| Independent Director | 4.42yrs | US$137.84k | 0.010% $19.3k | |
| Member of Scientific & Medical Advisory Board | 3yrs | no data | no data | |
| Director | 5yrs | US$185.51k | no data | |
| Member of Scientific & Medical Advisory Board | 3yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | 3yrs | no data | no data |
3.0yrs
Average Tenure
59yo
Average Age
Experienced Board: OCX's board of directors are considered experienced (3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: OCX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.3%.
Top Shareholders
Company Information
OncoCyte Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: OncoCyte Corporation
- Ticker: OCX
- Exchange: AMEX
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$185.521m
- Shares outstanding: 67.22m
- Website: https://www.oncocyte.com
Number of Employees
Location
- OncoCyte Corporation
- 15 Cushing
- Irvine
- California
- 92618
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| OCX | AMEX (NYSE MKT LLC) | Yes | Common Shares | US | USD | Dec 2015 |
| 7OC | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Dec 2015 |
| 0KCC | LSE (London Stock Exchange) | Yes | Common Shares | GB | USD | Dec 2015 |
Biography
OncoCyte Corporation engages in the development and commercialization of non-invasive blood-based diagnostic tests for the early detection of cancer. The company is developing DetermaVu, a non-invasive molecular lung cancer confirmatory diagnostic that is administered to patients as a blood test. It also develops diagnostic tests based on liquid biopsies for detecting breast cancer. The company was founded in 2009 and is headquartered in Irvine, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/05/31 06:17 |
| End of Day Share Price | 2020/05/29 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.